<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="music/PMC3330267/results/search/drugs/results.xml">
  <result pre="cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor antagonist" exact="memantine" post="(for a review of the evidence see Herrmann et"/>
  <result pre="(Herrmann et al., 2011) and the FDA has also approved" exact="donepezil" post="for moderate to severe disease. These drugs show as"/>
  <result pre="to be additive benefits of combining a cholinesterase inhibitor and" exact="memantine" post="(Tariot et al., 2004; Atri et al., 2008; Lopez"/>
  <result pre="treat aggression, agitation and psychosis. Efficacy has been demonstrated for" exact="risperidone" post="(especially 2â€‰mg/day) when prescribed for aggression, but for agitation"/>
  <result pre="doses should be used and long-term prescription avoided. Anticonvulsants, like" exact="carbamazepine" post="(useful for agitation), and benzodiazepines may be helpful in"/>
  <result pre="tested ones were not efficacious in AD. Calcium channel blocker" exact="nilvadipine" post="could also reduce the production and augment the clearance"/>
  <result pre="strategies in development include the use of nerve growth factor," exact="etanercept" post="and phosphodiesterase-5 inhibitors; interventions at the mitochondrial level (for"/>
  <result pre="T. ( 2009). Long-term effects of the concomitant use of" exact="memantine" post="with cholinesterase inhibition in Alzheimer disease . J. Neurol."/>
 </snippets>
</snippetsTree>
